Jiwesh Jha
Psychiatry · Allentown, PANPI 1295764595
Payments from drug & device makers
Across 343 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$636
- AbbVie$250
- plus $858 from 8 others
What the payments were for
- Food & beverage$6,88198%
- Education$1632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 97 | $1,903 |
| Teva Pharmaceuticals USA, Inc. | 62 | $1,174 |
| Johnson & Johnson | 44 | $1,145 |
| Neurocrine Biosciences, Inc. | 51 | $1,078 |
| Alkermes, Inc. | 31 | $636 |
| AbbVie(2 entities) | 14 | $250 |
| Indivior Inc. | 11 | $248 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $232 |
| Sunovion Pharmaceuticals Inc. | 10 | $192 |
| Noven Therapeutics, LLC | 7 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $42 |
| Lundbeck LLC | 1 | $19 |
| Eisai Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$7,044 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 48 | $165,211 |
| Abilify MaintenaAripiprazole | 44 | $124,211 |
| Fluphenazine Hcl | 13 | $7,025 |
| Aripiprazole | 57 | $5,531 |
| Clozapine | 42 | $2,403 |
| Haloperidol Decanoate | 27 | $1,448 |
| Divalproex Sodium | 44 | $966 |
| LoxapineLoxapine Succinate | 46 | $958 |
| Ziprasidone Hcl | 13 | $930 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $773 |
| Haloperidol | 21 | $651 |
| Benztropine Mesylate | 67 | $555 |
| Olanzapine | 18 | $453 |
| Quetiapine Fumarate | 39 | $413 |
| Mirtazapine | 53 | $382 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,145 | $165,21148 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,903 | $124,21144 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $1,174 | $95846 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Allentown
- Paul GrossAllentown$4.1M
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.